Disruption of the transforming growth factor-β pathway by tolfenamic acid via the ERK MAP kinase pathway

Carcinogenesis

Volumn 34, Issue 12, 2013, Pages 2900-2907

  Zhang, Xiaobo ^a,b   Min, Kyung Won ^a   Liggett, Jason ^a   Baek, Seung Joon ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b NORTHWEST A F UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; SMAD2 PROTEIN; SMAD3 PROTEIN; TOLFENAMIC ACID; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL DISRUPTION; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

CELL LINE, TUMOR; CELL NUCLEUS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; ORTHO-AMINOBENZOATES; PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84889050891     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt250     Document Type: Article

References (44)

1. Wrana,J.L. et al. (1994) Mechanism of activation of the TGF-beta receptor. Nature, 370, 341-347.
2. Shi,Y. et al. (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell, 113, 685-700.
3. Macías-Silva,M. et al. (1996) MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell, 87, 1215-1224.
4. Abdollah,S. et al. (1997) TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J. Biol. Chem., 272, 27678-27685.
5. Kretzschmar,M. et al. (1997) The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev., 11, 984-995.
6. Souchelnytskyi,S. et al. (1997) Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J. Biol. Chem., 272, 28107-28115.
7. Goumans,M.J. et al. (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J., 21, 1743-1753.
8. Wrighton,K.H. et al. (2009) Transforming growth factor {beta} can stimulate Smad1 phosphorylation independently of bone morphogenic protein receptors. J. Biol. Chem., 284, 9755-9763.
9. Liu,F. et al. (1997) Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev., 11, 3157-3167.
10. Zhou,S. et al. (1998) Characterization of human FAST-1, a TGF beta and activin signal transducer. Mol. Cell, 2, 121-127.
11. Labbé,E. et al. (1998) Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. Mol. Cell, 2, 109-120.
12. Zhang,Y. et al. (1998) Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature, 394, 909-913.
13. Massagué,J. (2008) TGFbeta in cancer. Cell, 134, 215-230.
14. Muraoka,R.S. et al. (2002) Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest., 109, 1551-1559.
15. Yang,Y.A. et al. (2002) Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest., 109, 1607-1615.
16. Subramanian,G. et al. (2004) Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res., 64, 5200-5211.
17. Halder,S.K. et al. (2005) A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia, 7, 509-521.
18. Hansen,P.E. (1994) Tolfenamic acid in acute and prophylactic treatment of migraine: a review. Pharmacol. Toxicol., 75 (suppl. 2), 81-82.
19. Abdelrahim,M. et al. (2006) Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J. Natl Cancer Inst., 98, 855-868.
20. Abdelrahim,M. et al. (2007) Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res., 67, 3286-3294.
21. Liu,X. et al. (2009) The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. Mol. Cancer Ther., 8, 1207-1217.
22. Papineni,S. et al. (2009) Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis, 30, 1193-1201.
23. Colon,J. et al. (2011) Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest. New Drugs, 29, 41-51.
24. Sankpal,U.T. et al. (2012) Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer. Prostate, 72, 1648-1658.
25. Lee,S.H. et al. (2008) ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol. Cancer Ther., 7, 3739-3750.
26. Lee,S.H. et al. (2010) Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways. Oncogene, 29, 5182-5192.
27. Kang,S.U. et al. (2012) Tolfenamic acid induces apoptosis and growth inhibition in head and neck cancer: involvement of NAG-1 expression. PLoS One, 7, e34988.
28. Baek,S.J. et al. (2005) Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol. Pharmacol., 67, 356-364.
29. Thuault,S. et al. (2006) Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J. Cell Biol., 174, 175-183.
30. Kretzschmar,M. et al. (1999) A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev., 13, 804-816.
31. Verrecchia,F. et al. (2003) A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven SMAD3/4-specific gene expression. J. Biol. Chem., 278, 1585-1593.
32. Derynck,R. et al. (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 425, 577-584.
33. Uhl,M. et al. (2004) SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res., 64, 7954-7961.
34. Prud'homme,G.J. (2007) Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab. Invest., 87, 1077-1091.
35. Kasai,H. et al. (2005) TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir. Res., 6, 56.
36. Fong,Y.C. et al. (2009) Transforming growth factor-beta1 increases cell migration and beta1 integrin up-regulation in human lung cancer cells. Lung Cancer, 64, 13-21.
37. Peinado,H. et al. (2004) Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol. Cell. Biol., 24, 306-319.
38. Alarcón,C. et al. (2009) Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell, 139, 757-769.
39. Javelaud,D. et al. (2005) Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGFbeta: implications for carcinogenesis. Oncogene, 24, 5742-5750.
40. Suzuki,K. et al. (2007) Transforming growth factor beta signaling via Ras in mesenchymal cells requires p21-activated kinase 2 for extracellular signal- regulated kinase-dependent transcriptional responses. Cancer Res., 67, 3673-3682.
41. Lo,R.S. et al. (2001) Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. EMBO J., 20, 128-136.
42. Seo,S.R. et al. (2006) Nuclear retention of the tumor suppressor cPML by the homeodomain protein TGIF restricts TGF-beta signaling. Mol. Cell, 23, 547-559.
43. Woodford-Richens,K.L. et al. (2001) SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proc. Natl Acad. Sci. USA, 98, 9719-9723.
44. Yamagata,H. et al. (2005) Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis. Cancer Res., 65, 157-165.